Valuation: Black Diamond Therapeutics, Inc.

Market Cap 101M 88.51M 82.42M 75.81M 142M 9.63B 145M 978M 383M 4.78B 379M 370M 16.51B P/E 2026 *
-2.72x
P/E 2027 * -1.75x
Enterprise Value 101M 88.51M 82.42M 75.81M 142M 9.63B 145M 978M 383M 4.78B 379M 370M 16.51B EV / Sales 2026 *
18.2x
EV / Sales 2027 * -
Free-Float
99.35%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 62 2023-09-15
Chief Tech/Sci/R&D Officer 51 2021-08-10
Director of Finance/CFO 41 2024-10-06
Director TitleAgeSince
Director/Board Member 61 2017-02-28
Director/Board Member 47 2019-11-30
Director/Board Member 49 2018-11-30
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 99.13M
-2.25%+1.55%+50.84%+70.04% 56.19B
-1.32%-2.71%+34.27%+77.57% 54.83B
+1.49%+0.13%-18.03%-13.94% 23.04B
-0.57%-4.13%+2.34%+387.73% 22.7B
-0.21%-0.62%+20.56%-10.90% 20.23B
0.00%+3.00%+27.41%-29.52% 17.83B
-0.97%-0.59%+33.12%+550.67% 15.65B
-6.69%-5.11%+169.13%+304.89% 15.24B
+1.25%+0.69%+27.30%+184.69% 14.03B
Average -0.93%-0.17%+38.55%+169.03% 26.64B
Weighted average by Cap. -1.17%-0.21%+36.53%+132.56%

Financials

2026 *2027 *
Net sales 5.56M 4.88M 4.54M 4.18M 7.83M 531M 7.96M 53.86M 21.08M 263M 20.86M 20.41M 909M -
Net income -40.47M -35.52M -33.08M -30.42M -57.03M -3.87B -58.01M -392M -154M -1.92B -152M -149M -6.63B -70.04M -61.47M -57.24M -52.65M -98.7M -6.69B -100M -679M -266M -3.32B -263M -257M -11.47B
Net Debt - -
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.760USD
Average target price
9.857USD
Spread / Average Target
+460.06%

Quarterly revenue - Rate of surprise